Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
Holding HOWL?
Track your performance easily
HOWL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.31 - $8.19
Previous CloseN/A
Volume113.58K
Average Volume (3M)340.90K
Market Cap
$59.71M
Enterprise Value$6.61M
Total Cash (Recent Filing)$17.90M
Total Debt (Recent Filing)$2.54M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 20, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding44,563,152
10 Day Avg. Volume311,947
30 Day Avg. Volume340,896
Standard Deviation0.26
R-Squared0.00481
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.64
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.12
Enterprise Value/Gross Profit4.23
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$10.50Price Target Upside689.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Advances Innovative Cytokine Therapies
PremiumStock Analysis & Ideas
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ StocksBulls Say, Bears Say
Bulls Say
Drug Development And Clinical ResultsThe WTX-330 prodrug showed early anti-tumor activity with a significant reduction in tumor size, highlighting the potential effectiveness of the treatment.
Partnership And Financial PositionWerewolf Therapeutics has a partnership with Jazz Pharmaceuticals and a strong cash position, indicating a promising investment opportunity.
Pipeline Expansion And InnovationWerewolf Therapeutics plans to expand its pipeline with candidates targeting IL-21 and IL-18, showing a commitment to broadening its therapeutic offerings.
Bears Say
Financial PerformanceWerewolf reported no revenues for 3Q24, which could be a concern for potential investors looking for immediate earnings.
Stock ValuationThe price target for Werewolf Therapeutics has been lowered to $4 from $12 based on a cash/share and platform value analysis.
Treatment EfficacyWTX-330's overall breadth and depth of response was modest with suboptimal durability, and coincided with on-mechanism dose-limiting toxicities and high-grade adverse events.
---
Ownership Overview
28.00%
Insiders
5.22% Mutual Funds
49.13% Other Institutional Investors
11.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $1.31 and its highest was $8.19 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $59.71M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.025.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 44,563,152 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went down -8.197%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
---
Werewolf Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (689.47% Upside)
$10.50 (689.47% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 125.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.76%
12-Months-Change
Fundamentals
Return on Equity
-61.56%
Trailing 12-Months
Asset Growth
-20.61%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
---
HOWL Stock 12 Month Forecast
Average Price Target
$10.50
▲(689.47% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Gritstone bio
―
Oragenics
―
GlycoMimetics
―
Palvella Therapeutics
―
Cardiff Oncology
―
Best Analysts Covering HOWL
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-0.42%
reiterated a buy rating 6 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -0.42% per trade.
---